Capivasertib Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of capivasertib during breastfeeding. Because of its potential toxicity in the breastfed infant, the manufacturer recommends that breastfeeding be discontinued during capivasertib therapy. With a half-life of 8.3 hours the drug should be cleared from the maternal bloodstream in 2 days. However, capivasertib is used in combination with fulvestrant, which may increase the risk to the infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Capivasertib
CAS Registry Number
1143532-39-1
Drug Class
Breast Feeding
Lactation
Milk, Human
Antineoplastic Agents
Enzyme Inhibitors
Protein Kinase Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
